文献速递肝病消化道肿瘤与早癌

抗病毒治疗期间LSM可可靠预测显著纤维化及肝硬化CHB患者的肝脏相关事件

Early on-treatment LSM reliably predicts liver-related events in CHB patients with significant fibrosis and cirrhosis.
PubMed 文献 · Hepatology · 2025-09-01

该前瞻性队列纳入1116例接受抗病毒治疗的慢性乙型肝炎(CHB)显著纤维化或肝硬化患者,中位随访7.5年。治疗1–3年时的LSM是3年和5年结局最可靠的预测指标(AUROC 0.72–0.78),优于基线LSM和LSM变化;治疗1、2、3年LSM<10 kPa者5年累积LRE发生率分别为2.2%、2.6%、2.7%。

要点

  • 治疗1–3年时的LSM预测LRE优于基线LSM和LSM动态变化。
  • 治疗1、2、3年LSM<10 kPa者5年LRE累积发生率分别为2.2%、2.6%、2.7%。
  • LSM<10 kPa与肝活检小叶结构更好恢复相关,肝硬化亚组和验证队列结果一致。

核心结论

  • 抗病毒治疗1–3年时测量的on-treatment LSM对LRE的预测准确性优于基线LSM或LSM变化。
  • 治疗期间LSM<10 kPa提示LRE风险显著更低,可能与小叶结构改善有关。

研究设计与样本

  • 前瞻性队列研究,纳入1116例CHB伴显著纤维化或肝硬化患者,其中875例(78.4%)诊断为肝硬化。
  • 中位随访7.5(2.5–9.5)年,分析基线、治疗期间及动态LSM变化与LRE的关联。
  • LRE定义为肝功能失代偿、肝移植或肝病相关死亡。

主要发现

  • 治疗1–3年时on-treatment LSM预测3年和5年结局的AUROC为0.72–0.78,优于基线LSM(AUROC 0.59–0.65)和LSM变化(AUROC 0.42–0.65)。
  • 治疗1、2、3年LSM<10 kPa者5年LRE累积发生率分别为2.2%、2.6%、2.7%。
  • 上述结果在肝硬化亚组、验证队列及单独预测失代偿时均成立。
  • 治疗期间LSM<10 kPa者肝活检显示小叶结构恢复更好。

关键数值与推荐

  • on-treatment LSM<10 kPa(治疗1、2或3年时)对应5年LRE累积发生率分别为2.2%、2.6%、2.7%。
  • on-treatment LSM预测3年和5年结局的AUROC为0.72–0.78;基线LSM为0.59–0.65;LSM变化为0.42–0.65。

临床怎么用

  • 对接受抗病毒治疗的CHB伴显著纤维化或肝硬化患者,可在治疗1–3年时采用on-treatment LSM评估LRE风险。
  • 治疗1–3年LSM<10 kPa提示LRE风险较低,可据此辅助风险分层与随访管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Evidence comparing longitudinal liver stiffness measurements (LSMs) dynamics to on-treatment LSM for predicting clinical outcomes in patients receiving etiology therapy is limited. This study aimed to assess the prognostic value of on-treatment LSM in patients with chronic hepatitis B (CHB) receiving antiviral therapy. APPROACH AND RESULTS: This prospective cohort included patients with CHB and significant fibrosis or cirrhosis. Liver-related events (LREs) were defined as hepatic decompensation, liver transplantation, or liver-related death. The association between LREs and baseline, on-treatment, and dynamic changes in LSM was analyzed. A total of 1116 patients with CHB, including 875 (78.4%) diagnosed with cirrhosis, were followed for a median of 7.5 (2.5-9.5) years. On-treatment LSM was the most reliable predictor of 3-year and 5-year outcomes (AUROC: 0.72-0.78) after 1-3 years of antiviral therapy, outperforming baseline LSM (AUROC: 0.59-0.65) and LSM changes (AUROC: 0.42-0.65).Patients with LSM <10 kPa at 1, 2, or 3 years of antiviral therapy have a much lower risk of LREs, with a 5-year cumulative incidence of 2.2%, 2.6%, and 2.7%, respectively. This finding held true in the cirrhosis subgroup, in the validation cohort, and for predicting decompensations alone. Notably, patients with on-treatment LSM <10 kPa showed better restoration of lobular architecture assessed by liver biopsies. CONCLUSIONS: On-treatment LSM measured 1-3 years after antiviral therapy offers superior predictive accuracy for LREs compared with baseline or LSM changes, with LSM <10 kPa indicating a significantly lower risk, likely due to improved lobular architecture.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Sun Y, Chen S, Xu X, et al. Early on-treatment LSM reliably predicts liver-related events in CHB patients with significant fibrosis and cirrhosis. Hepatology. 2025. PMID: 40888242. doi:10.1097/HEP.0000000000001504

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。